C$
3.72
May 31
Business Description
HLS Therapeutics Inc
NAICS : 325412
SIC : 3741
ISIN : CA40390B1094
Description
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.23 | |||||
Equity-to-Asset | 0.45 | |||||
Debt-to-Equity | 0.96 | |||||
Debt-to-EBITDA | 7.85 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -0.71 | |||||
Beneish M-Score | -3.3 | |||||
WACC vs ROIC |
Growth Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 5 | |||||
3-Year EBITDA Growth Rate | -17 | |||||
3-Year EPS without NRI Growth Rate | -5 | |||||
3-Year Book Growth Rate | -15.6 | |||||
Future 3-5Y Total Revenue Growth Rate | 11.32 |
Momentum Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 36.62 | |||||
9-Day RSI | 35.1 | |||||
14-Day RSI | 35.9 | |||||
6-1 Month Momentum % | 33.24 | |||||
12-1 Month Momentum % | 10.45 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.56 | |||||
Quick Ratio | 1.17 | |||||
Cash Ratio | 0.74 | |||||
Days Inventory | 451.87 | |||||
Days Sales Outstanding | 56.75 | |||||
Days Payable | 620.95 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 1.34 | |||||
3-Year Dividend Growth Rate | -19.5 | |||||
5-Year Yield-on-Cost % | 2.22 | |||||
3-Year Average Share Buyback Ratio | -0.2 | |||||
Shareholder Yield % | 10.05 |
Profitability Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 86.91 | |||||
Operating Margin % | -17.51 | |||||
Net Margin % | -45.77 | |||||
FCF Margin % | 20.65 | |||||
ROE % | -26.7 | |||||
ROA % | -12.79 | |||||
ROIC % | -5.62 | |||||
ROC (Joel Greenblatt) % | -651.37 | |||||
ROCE % | -9.83 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 1.47 | |||||
PB Ratio | 0.98 | |||||
Price-to-Free-Cash-Flow | 7.1 | |||||
Price-to-Operating-Cash-Flow | 7.1 | |||||
EV-to-EBIT | -8.32 | |||||
EV-to-EBITDA | 14.19 | |||||
EV-to-Revenue | 2.55 | |||||
EV-to-Forward-Revenue | 2.59 | |||||
EV-to-FCF | 12.34 | |||||
Price-to-Projected-FCF | 0.57 | |||||
Earnings Yield (Greenblatt) % | -12.02 | |||||
FCF Yield % | 14.25 | |||||
Forward Rate of Return (Yacktman) % | -9.46 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
HLS Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil C$) | 81.677 | ||
EPS (TTM) (C$) | -1.154 | ||
Beta | 0.96 | ||
Volatility % | 66.13 | ||
14-Day RSI | 35.9 | ||
14-Day ATR (C$) | 0.142668 | ||
20-Day SMA (C$) | 4.073 | ||
12-1 Month Momentum % | 10.45 | ||
52-Week Range (C$) | 3.34 - 7.12 | ||
Shares Outstanding (Mil) | 31.81 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
HLS Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
HLS Therapeutics Inc Stock Events
Event | Date | Price(C$) | ||
---|---|---|---|---|
No Event Data |
HLS Therapeutics Inc Frequently Asked Questions
What is HLS Therapeutics Inc(TSX:HLS)'s stock price today?
When is next earnings date of HLS Therapeutics Inc(TSX:HLS)?
Does HLS Therapeutics Inc(TSX:HLS) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |